Xtant Medical (NYSEAMERICAN:XTNT)‘s stock had its “buy” rating reissued by equities research analysts at Maxim Group in a research note issued to investors on Wednesday. They currently have a $10.00 price target on the medical device company’s stock. Maxim Group’s price objective would suggest a potential upside of 110.97% from the stock’s current price.
Shares of Xtant Medical (NYSEAMERICAN XTNT) traded down $0.04 during trading on Wednesday, hitting $4.74. The stock had a trading volume of 13,497 shares, compared to its average volume of 14,093. The firm has a market capitalization of $7.88, a price-to-earnings ratio of -2.91 and a beta of 0.41. Xtant Medical has a twelve month low of $3.96 and a twelve month high of $14.52.
Xtant Medical (NYSEAMERICAN:XTNT) last announced its quarterly earnings data on Tuesday, November 21st. The medical device company reported ($0.47) earnings per share for the quarter. The firm had revenue of $19.79 million during the quarter.
About Xtant Medical
Xtant Medical Holdings, Inc, formerly Bacterin International Holdings, Inc, develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. The Company operates through the development, manufacture and marketing of regenerative medical products and devices segment.
Receive News & Ratings for Xtant Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xtant Medical and related companies with MarketBeat.com's FREE daily email newsletter.